PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
Laura Rosa MangiapaneAnnalisa NicotraAlice TurdoMiriam GaggianesiPaola BiancaSimone Di FrancoDavide Stefano SardinaVeronica VeschiMichele SignoreSven BeyesLuca FagnocchiMicol Eleonora FioriMaria Rita BongiornoMelania Lo IaconoIrene PillitteriGloria GanduscioGaspare GulottaJan Paul MedemaAlessio ZippoMatilde TodaroRuggero De MariaGiorgio StassiPublished in: Gut (2021)
While PI3K targeting kills liver-colonising CR-CSCs, the concomitant inhibition of PI3K, HER2 and MEK is required to induce regression of tumours resistant to anti-EGFR therapies. These data may provide a rationale for designing clinical trials in the adjuvant and metastatic setting.
Keyphrases
- stem cells
- clinical trial
- small cell lung cancer
- poor prognosis
- squamous cell carcinoma
- epidermal growth factor receptor
- early stage
- electronic health record
- tyrosine kinase
- big data
- cancer therapy
- binding protein
- cancer stem cells
- phase ii
- cell therapy
- long non coding rna
- open label
- human health
- double blind
- risk assessment
- drug delivery
- data analysis